Close Menu

NEW YORK (GenomeWeb) – Taiwanese diagnostics firm PlexBio said today that it received CE marking for its IntelliPlex Lung Cancer Panel, an in vitro molecular diagnostic assay for the qualitative identification of 36 DNA mutations.

The assay can identify mutations in the KRAS, NRAS, PIK3CA, BRAF, and EGFR genes, as well as 19 gene rearrangements of the ALK, ROS1, RET, NTRK1, and MET genes from formalin-fixed, paraffin-embedded tumor tissue from lung cancer patients, PlexBio said. It added that the assay leverages its SelectAmp and πCode technologies.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.